Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial.
about
Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repairCONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trialsCost-effectiveness of prolonged thromboprophylaxis after cancer surgery.Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.Low-molecular-weight heparins: weeks or months instead of days of treatment.Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists.Prevention of postoperative venous thromboembolism. Risk assessment and methods of prophylaxis.Risk Factor Analysis for 30-Day Mortality After Primary THA in a Single InstitutionPotent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplastyEffects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C--a randomized trial.Discontinuation of warfarin is unnecessary in total knee arthroplasty.A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery.Pharmacologic prophylaxis and treatment of venous thromboembolism after knee arthroplasty.Comparison of three different anti-Xa assays in major orthopedic surgery patients treated with direct oral anticoagulant.Meeting the unmet needs in anticoagulant therapy.Cost-effectiveness of extended venous thromboembolism prophylaxis with fondaparinux in hip surgery patients.Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty.Regarding clinical practice guidelines on the use of warfarin.Low-molecular-weight heparin prophylaxis against thromboembolism after total hip replacement--the never-ending story?Thromboembolic complications in burn patients and associated risk factors.The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.Reply to Letter to Editor: Potent Anticoagulants are Associated with a Higher All-cause Mortality Rate after Hip and Knee Arthroplasty.Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery.The Evaluation of Fibrin-Related Markers for Diagnosing or Predicting Acute or Subclinical Venous Thromboembolism in Patients Undergoing Major Orthopedic Surgery.Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux.Elevated soluble platelet glycoprotein VI is a useful marker for DVT in postoperative patients treated with edoxaban.Prolonged outpatient vitamin K antagonist use and risk of venous thromboembolism in patients undergoing total hip or knee replacement
P2860
Q24185998-FF0C381C-5D74-4DB2-AEB0-A5409479E33EQ24614627-4F92EB36-4D6E-41AE-9D57-46945C785F00Q33385989-36C18AAA-3752-4A8E-B837-CF786ADC77ECQ33605199-7A0BDB27-F42D-45C8-8E4E-75B9FDE225D8Q34430449-536613A1-28DB-464D-8EA4-3844E7FEAB42Q36062161-890DC06E-9C8F-49BC-AF73-E6EE1BF4E8C6Q36503092-03BC3CE2-53A2-48F9-BD7B-A317863A0841Q37025246-FED397DA-123C-4CDD-A473-DF498F932AEAQ37081079-2F0235FE-8BB0-45C1-B8DF-6AAF58612E3EQ37115792-D2A2DC3D-70C5-4B12-85E0-FD23E40C0549Q37483354-2A3E73C5-9540-4588-9750-27166E81D81EQ37876398-3DCEA456-9276-40E0-9D7C-6E4D91D87DB9Q41989815-42D28C95-508D-4644-936C-A71CAFEE08DBQ42375169-625BA49E-C030-476F-A03A-F393581CFAB0Q43018499-EB3C5FEE-0A8E-4D0B-A00E-8F0E4841BEDDQ43042771-6E8C2AAE-A7B8-4E17-B6F3-668DBAEEA6A7Q43242110-450B757A-A64A-4802-BAC3-4ED6D7E073C4Q43530498-8A6B34AA-DE8C-4BDC-97FF-2CE0495229A9Q43617256-B5C778C0-D914-4C1A-AB18-B89BA472E170Q43785240-44E0A2A1-E959-4B66-B956-A78CC3427122Q44604237-6BBD92C4-C2E9-4BDB-9860-D2F60AAEA9B1Q45752159-9B711533-C1B8-45A7-9514-53779A96A827Q46428749-1E0EFDCB-8841-4122-8A70-DCAB15513A16Q47305705-D957C12E-AFB0-41C5-9997-26FD08CCB555Q53348418-5D1ECF7B-F48A-4907-B9EF-9605DB9A3ACCQ54451675-E2D0407F-1BA6-4904-A8A6-8BB355CE0344Q55058563-C9DA3DF5-88F9-456B-9589-DD01D3534276Q57086698-14D4F108-362B-4075-B761-3C3930FE279A
P2860
Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Ardeparin sodium for extended ...... ind, placebo-controlled trial.
@ast
Ardeparin sodium for extended ...... ind, placebo-controlled trial.
@en
Ardeparin sodium for extended ...... ind, placebo-controlled trial.
@nl
type
label
Ardeparin sodium for extended ...... ind, placebo-controlled trial.
@ast
Ardeparin sodium for extended ...... ind, placebo-controlled trial.
@en
Ardeparin sodium for extended ...... ind, placebo-controlled trial.
@nl
prefLabel
Ardeparin sodium for extended ...... ind, placebo-controlled trial.
@ast
Ardeparin sodium for extended ...... ind, placebo-controlled trial.
@en
Ardeparin sodium for extended ...... ind, placebo-controlled trial.
@nl
P2093
P1476
Ardeparin sodium for extended ...... ind, placebo-controlled trial.
@en
P2093
P304
P356
10.7326/0003-4819-132-11-200006060-00002
P407
P577
2000-06-01T00:00:00Z